These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24593323)

  • 1. Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines.
    Kim BJ; Kwon HH; Park SY; Min SU; Yoon JY; Park YM; Seo SH; Ahn JY; Lee HK; Suh DH
    J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1761-7. PubMed ID: 24593323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study.
    Won CH; Lee HM; Lee WS; Kang H; Kim BJ; Kim WS; Lee JH; Lee DH; Huh CH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):171-8. PubMed ID: 23301821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of a New Botulinum Toxin (HU-014) Versus Existing Onabotulinumtoxin A in Subjects With Moderate to Severe Glabellar Lines.
    Yoo KH; Lee YW; Lee JS; Kwon SH; Huh CH; Kim BJ
    Dermatol Surg; 2021 Mar; 47(3):e91-e96. PubMed ID: 33481449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study.
    Won CH; Kim HK; Kim BJ; Kang H; Hong JP; Lee SY; Kim CS
    Int J Dermatol; 2015 Feb; 54(2):227-34. PubMed ID: 25311357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
    Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
    Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
    Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
    Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of forehead/glabellar rhytide complex with combination botulinum toxin a and hyaluronic acid versus botulinum toxin A injection alone: a split-face, rater-blinded, randomized control trial.
    Dubina M; Tung R; Bolotin D; Mahoney AM; Tayebi B; Sato M; Mulinari-Brenner F; Jones T; West DP; Poon E; Nodzenski M; Alam M
    J Cosmet Dermatol; 2013 Dec; 12(4):261-6. PubMed ID: 24305424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
    Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
    Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
    Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
    Alimohammadi M; Andersson M; Punga AR
    Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.
    Cheon HI; Jung N; Won CH; Kim BJ; Lee YW
    Dermatol Surg; 2019 Dec; 45(12):1610-1619. PubMed ID: 30893169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids.
    Beer KR
    Dermatol Surg; 2006 Feb; 32(2):184-97. PubMed ID: 16442037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids.
    Carruthers A; Carruthers J
    Dermatol Surg; 2005 Oct; 31(10):1297-303. PubMed ID: 16188182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, double-blind, randomized, parallel-group, active-controlled, phase 3 clinical trial to compare the effectiveness and safety of two botulinum toxin type A formulations for improving moderate to severe glabellar wrinkles in Asians.
    Choi SY; Koh YG; Lee YW; Son HS; Yoon YN; Kim G; Won C; Cho H; Son JS; Kim EK; Kim BJ
    J Dermatolog Treat; 2024 Dec; 35(1):2359511. PubMed ID: 38880494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
    Carruthers A; Carruthers J; Said S
    Dermatol Surg; 2005 Apr; 31(4):414-22; discussion 422. PubMed ID: 15871316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines.
    Frampton JE; Easthope SE
    Am J Clin Dermatol; 2003; 4(10):709-25. PubMed ID: 14507232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.